DOCSLIB.ORG

TRACKING HIV and HEPATITIS VIRUSES TRACKINGHIV and Hepatitis Viruses HIV Can Evolve and Into New HEPATITIS and Di Erent Strains

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TRACKING HIV and HEPATITIS VIRUSES TRACKINGHIV and Hepatitis Viruses HIV Can Evolve and Into New HEPATITIS and Di Erent Strains ABBOTT BEHIND THE SCIENCE Virus Hunters TRACKING HIV AND HEPATITIS VIRUSES TRACKINGHIV and hepatitis viruses HIV can evolve AND into new HEPATITIS and dierent strains. AbbottVIRUSES is committed HIVto ongoing and hepatitis research viruses to help can our evolve tests to keep produce pace dierentwith these strains. viruses. Abbott In 1994, is committed Abbott to ongoingestablished research the Global to ensure Viral that Surveillance our diagnostic Program tools to keep monitor pace andwith track these new viruses. viral More thanstrains 20 aroundyears ago, the Abbott world. established the Global Surveillance Program to monitor and track new viral strains around the world. SAMPLES COLLECTED FROM 45 COUNTRIES ARGENTINA IVORY COAST AUSTRALIA KENYA ACROSS 6 CONTINENTS AUSTRIA LAOS SURVEILLANCE COLLECTION SITES IN 40 COUNTRIES, COVERING 6 CONTINENTS BRAZIL MEXICO BURUNDI NIGERIA ABBOTTAbbott PARK,Park, Illinois:ILLINOIS: Abbott’s ABBOTT’S Global CAMEROON- Argentina PAKISTAN- Italy GLOBALSurveillance VIRAL Program SURVEILLANCE houses more than CHINA- Australia PERU- Ivory Coast PROGRAM HOUSES MORE THAN 60,000 samples containing HIV and COLOMBIA- Brazil PHILIPPINES- Kenya 78,000 SAMPLES CONTAINING HIV - Burundi - Laos ANDhepatitis HEPATITIS viruses, VIRUSES, making MAKING it one of the DEMOCRATIC PORTUGAL - Cameroon - Mexico IT ONE OF THE LARGEST SUCH 1 REPUBLIC ROMANIA largest such libraries in the world. - China - Nepal LIBRARIES IN THE WORLD.1 OF THE CONGO - Colombia RUSSIA- Nigeria CROATIA- Democratic Republic SAUDI- Pakistan ARABIA EGYPT- of the Congo SENEGAL- Philippines EQUATORIAL- Croatia GUINEA SOUTH- Russia AFRICA - Egypt Saudi Arabia FRANCE SPAIN- - England - Senegal GERMANY SWITZERLAND - Equatorial Guinea - South Africa GHANA- France THAILAND- Spain GREECE- Germany UGANDA- Thailand GUINEABISSAU- Ghana UNITED- Turkey HAITI- Greece KINGDOM- Uganda - Guinea-Bissau - USA HONDURAS UNITED STATES - Haiti - Venezuela INDIA- Honduras VENEZUELA- Vietnam ISRAEL- India VIETNAM ITALY ZAMBIA Abbott identified and characterized Abbott identified and characterized When a new strain is discovered, Abbott has identified and Abbott has identified and Abbott has identified a new strain Abbott’s research to monitor characterizedmore than more 5,000 than virus 5,000 strains, enablingcharacterized rarerare HIV HIV Group Group N N and P ofviruses. HIV-1, Group M: Subtype Abbott L.confirms ourthe current diversity blood of HIV screening and hepatitis virusdiagnostic strains so tests our tests to detect can a wide rangeand P viruses. AbbottAbbott is 1 of is only1 of only2 2 institutionsAbbott has made the newand strain diagnostic testsviruses are able globally to detect helps itour tests detect aof wide HIV range and hepatitisof HIV viruses.1-2 institutions in thein the world world to to have doneavailable so.2-5 to the research communityand then updates them,stay as upneeded. to date.2 and hepatitis viruses.1-2 have done so.2-5 to evaluate this subtype’s impact on diagnostic testing, treatments and to potential vaccines.6 For more information, please visit abbott.com/virushunters. FOR MORE INFORMATION, PLEASE VISIT ABBOTT.COM/VIRUSHUNTERS. 1. Abbott internal data. 2. Brennan CA, Bodelle P, Coey R, et al. HIV global surveillance: Foundation for retroviral discovery and assay development. Journal of Medical Virology. 2006; 78: S24-S29. 1. Abbott internal data. 2. Brennan CA, Bodelle P, Coey R, et al. HIV global surveillance: Foundation for retroviral discovery and assay development. Journal of Medical Virology. 2006;78:S24-S29. 3. Rodgers M, Vallari A, Harris B, et al. Identification of rare HIV-1 Group N, HBV AE, and HTLV-3 strains in rural South Cameroon. Virology. 2017; 504: 141-51. 4. Rodgers M, Wilkinson E, Vallari A, 3. Bodelle P, Vallari A, Coey R, et. al. Identification and genomic sequence of an HIV type 1 group N isolate from Cameroon. AIDS Research and Human Retroviruses. 2004;20:900-906. et al. Sensitive next-generation sequencing method reveals deep genetic diversity of HIV-1 in the Democratic Republic of the Congo. Journal of Virology. 2017; 91: e01841-16. 4. Yamaguchi J, McArthur CP, Vallari A, et al. HIV-1 group N: Evidence for ongoing transmission in Cameroon. AIDS Research and Human Retroviruses. 2006;22:453-457. 5. Vallari A, Holzmayer V, Harris B, et al. Confirmation of putative HIV-1 group P in Cameroon. Journal of Virology. 2011;85:1403-1407. 6. Yamaguchi J, Vallari A, McArthur C, Sthreshley L, Cloherty G, Berg M, Rodgers MA. Complete genome sequence of CG-0018a-01 establishes HIV-1 subtype L. Journal of Acquired Immune Deficiency Syndromes. 2019..
Load more

Recommended publications
  • Filovirus Research in Gabon and Equatorial Africa: the Experience of a Research Center in the Heart of Africa
    Viruses 2012, 4, 1592-1604; doi:10.3390/v4091592 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Article Filovirus Research in Gabon and Equatorial Africa: The Experience of a Research Center in the Heart of Africa Eric Leroy 1,2,* and Jean Paul Gonzalez 1,2,3 1 Centre International de Recherches Médicales de Franceville (Franceville International Center for Medical Research), CIRMF, Libreville BP 2105, Gabon; E-Mail: [email protected] 2 Institut de Recherche pour le Développement, IRD, Marseille 13055, France 3 French Ministry of Foreign and European Affairs, French Embassy 75116, Gabon * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +241-01677-106; Fax: +241-01677-295. Received: 13 August 2012; in revised form 30 August 2012 / Accepted: 30 August 2012 / Published: 13 September 2012 Abstract: Health research programs targeting the population of Gabon and Equatorial Africa at the International Center for Medical Research in Franceville (CIRMF), Gabon, have evolved during the years since its inception in 1979 in accordance with emerging diseases. Since the reemergence of Ebola virus in Central Africa, the CIRMF “Emerging Viral Disease Unit” developed diagnostic tools and epidemiologic strategies and transfers of such technology to support the response of the National Public Health System and the World Health Organization to epidemics of Ebola virus disease. The Unit carries out a unique investigation program on the natural history of the filoviruses, emergence of epidemics, and Ebola virus pathogenesis. In addition, academic training is provided at all levels to regional and international students covering emerging conditions (host factors, molecular biology, genetics) that favor the spread of viral diseases.
    [Show full text]
  • Ten Years in Public Health, 2007–2017: Report by Dr Margaret Chan, Director-General, World Health Organization
    TEN YEARS IN PUBLIC HEALTH 2007-2017 REPORT BY DR MARGARET CHAN, DIRECTOR-GENERAL, WORLD HEALTH ORGANIZATION TEN YEARS IN PUBLIC HEALTH 2007-2017 REPORT BY DR MARGARET CHAN, DIRECTOR-GENERAL, WORLD HEALTH ORGANIZATION Ten years in public health, 2007–2017: report by Dr Margaret Chan, Director-General, World Health Organization ISBN 978-92-4-151244-2 © World Health Organization 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Ten years in public health, 2007–2017: report by Dr Margaret Chan, Director-General, World Health Organization.
    [Show full text]
  • Solving the COVID-19 Vaccine Product Liability Problem
    Solving the COVID-19 Vaccine Product Liability Problem Sam F. Halabi CSAS Working Paper 21-11 Public Health: Regulation, Innovation, and Preparation Solving the COVID-19 Vaccine Product Liability Problem SAM F. HALABI* ABSTRACT The global roll-out of COVID-19 vaccines is under way. Governments have invested billions of dollars in supporting research, development, logistics and supply chains, as well as networks of healthcare providers to deliver vaccines to recipients all over the world. The European Commission and several international organizations have established the COVAX Facility to pool resources in promising candidates and to subsidize their procurement by low- and middle-income countries. Yet up- front investment in vaccine development and delivery solves only half the problem with respect to vaccine access. Risks of legal liabilities, particularly product liability for severe side effects, will serve as an important, if not decisive, factor in how vaccine manufacturers participate in the response with emergency use authorized and recently licensed COVID-19 vaccines. If they do not receive sufficient assurance against legal liability, especially product liability, they will not ship vaccines. There is limited experience with developing coronavirus vaccines, and severe side effects following immunization are inevitable, as evidence from Phase III trials and early administration of EUA vaccines strongly suggests. Therefore, there is a critical need to balance the risk calculations of manufacturers with the justice for immunization
    [Show full text]
  • Accelerating Access to Hepatitis C Diagnostics and Treatment
    Accelerating access to hepatitis C diagnostics and treatment Overcoming barriers in low- and middle-income countries Global progress report 2020 Accelerating access to hepatitis C diagnostics and treatment Overcoming barriers in low- and middle-income countries Global progress report 2020 Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020 ISBN 978-92-4-001900-3 (electronic version) ISBN 978-92-4-001901-0 (print version) © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).
    [Show full text]
  • NEXT PANDEMIC an International Network for Monitoring the Fl Ow of Viruses from Animals to Humans Might Help Scientists Head Off Global Epidemics by Nathan Wolfe
    PUBLIC HEALTH PREVENTING THE NEXT PANDEMIC An international network for monitoring the fl ow of viruses from animals to humans might help scientists head off global epidemics By Nathan Wolfe weat streamed down my back, thorny As the chimps feasted on the monkey’s raw KEY CONCEPTS shrubs cut my arms, and we were losing fl esh and entrails, I thought about how this them again. The wild chimpanzees my scene contained all the elements of a perfect ■ Most human infectious S colleagues and I had been following for nearly storm for allowing microorganisms to jump diseases originated in animals. fi ve hours had stopped their grunting, hooting from one species to the next, akin to space trav- and screeching. Usually these calls helped us elers leaping at warp speed from one galaxy to ■ Historically, epidemiolo- follow the animals through Uganda’s Kibale another. Any disease-causing agent present in gists have focused on Forest. For three large males to quiet abruptly that monkey now had the ideal conditions un- domestic animals as the surely meant trouble. Suddenly, as we ap- der which to enter a new type of host: the chimps source of these scourges. But wild animals, too, have proached a small clearing, we spotted them were handling and consuming fresh organs; transmitted many diseas- standing below a massive fi g tree and looking their hands were covered with blood, saliva and es to us, including HIV. up at a troop of red colobus monkeys eating and feces, all of which can carry pathogens; blood playing in the treetop.
    [Show full text]
  • AIDS Data 2016
    UNAIDS 2016 | REFERENCE AIDS DATA Sudan 26 000 Eritrea Djibouti 8900 5300 Yemen Lebanon Tunisia 3800 <500 Swaziland <1000 130 000 Algeria United Republic Morocco 4000 of Tanzania 8900 820 000 Iran (Islamic Namibia Rwanda Republic of) 130 000 120 000 Egypt 26 000 3500 Somalia Angola 15 000 190 000 Malawi Mauritius 580 000 2100 Botswana Zimbabwe 200 000 830 000 Liberia Burkina Faso 18 000 Lesotho 57 000 Central 180 000 Benin African Republic Guinea 69 000 40 000 71 000 Kenya Burundi 880 000 Niger Cameroon 46 000 Chad Sierra Leone 25 000 360 000 97 000 31 000 South Sudan South Africa Mauritania 100 000 4 100 000 Mali Ghana 7300 72 000 160 000 Uganda 840 000 Gabon Mozambique 31 000 890 000 Zambia Democratic Republic Nigeria Côte d’Ivoire Madagascar Cabo Verde 690 000 of the Congo 270 000 21 000 1700 220 000 Senegal Gambia 28 000 Togo 12 000 63 000 Equatorial Guinea 15 000 CONTENTS Introduction 2 Data summary 3 New HIV infections—all ages 10 New HIV infections—children aged 0–14 years 14 People living with HIV—all ages 18 People dying from AIDS-related illnesses 22 Pregnant women accessing medicines to prevent HIV transmission to their baby 26 People living with HIV on HIV treatment—adults 15 years and older 30 People living with HIV on HIV treatment—children aged 0–14 years 34 People living with HIV on HIV treatment—women and men 15 years and older 38 International assistance for the AIDS response 42 Domestic public and international expenditure for the AIDS response 55 Data collection and analysis methodology 72 INTRODUCTION The old saying “What gets measured gets done” may be a cliché, but is still very true for the response to HIV.
    [Show full text]
  • Undetectable How Viral Load Monitoring Can Improve Hiv Treatment in Developing Countries
    © Treatment Action Campaign © Treatment UNDETECTABLE HOW VIRAL LOAD MONITORING CAN IMPROVE HIV TREATMENT IN DEVELOPING COUNTRIES www.msfaccess.org TABLE OF CONTENTS 3 EXECUTIVE SUMMARY 4 INTRODUCTION 5 MSF HIV/AIDS Treatment Programmes (Figure 1) 7 PART 1: WHY WE NEED ROUTINE VIRAL LOAD MONITORING 7 Virological monitoring detects treatment failure earlier (Figure 2) 7 I. Adherence counselling: Viral load enables efforts to be targeted 9 Viral load and transmission of HIV 9 II. Drug resistance: Viral load helps to confirm treatment failure 10 Looking to the future: A viral load test able to detect resistance? 10 The evidence base: The advantages of routine viral load over clinical or immunological monitoring 13 PART 2: Implementation OF VIRAL LOAD IN THE DEVELOPING WORLD 13 I. Limited uptake 13 Guidelines in countries with the highest HIV prevalence (Table 1) 14 II. Recommendations for use of viral load monitoring 15 Can viral load improve early infant diagnosis? 17 P ART 3: HOW TO ENSURE WIDER implementation OF VIRAL LOAD: OVERCOMING TECHNICAL BARRIERS 18 Commercially available viral load tests (Table 2) 21 Getting viral load to remote settings: The use of DBS from fingerprick blood 22 Ensuring quality: The reliability of laboratory results and of diagnostic tests 23 Wish list of viral load test specifications for resource limited settings (Table 3) 24 Pipeline viral load tests (Table 4) 26 Getting viral load to remote settings: MSF field trials of the SAMBA test 29 P ART 4: HOW TO ENSURE WIDER implementation OF VIRAL LOAD: OVERCOMING
    [Show full text]
  • Re-Emergence of Crimean-Congo Hemorrhagic Fever Virus in Central Africa
    Re-Emergence of Crimean-Congo Hemorrhagic Fever Virus in Central Africa Gilda Grard1*, Jan Felix Drexler2, Joseph Fair3, Jean-Jacques Muyembe4, Nathan D. Wolfe3,5, Christian Drosten2, Eric M. Leroy1,6 1 Centre International de Recherches Me´dicales de Franceville (CIRMF), Franceville, Gabon, 2 Institute of Virology, University of Bonn Medical Centre, Bonn, Germany, 3 Global Viral Forecasting, San Francisco, California, United States of America, 4 Institut National de Recherche Biome´dicale, Kinshasa, Democratic Republic of the Congo, 5 Department of Epidemiology, School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America, 6 Institut de Recherche pour le De´veloppement (IRD), UMR 224 (MIVEGEC), IRD/CNRS/UM1, Montpellier, France Abstract Background: Crimean-Congo hemorrhagic fever (CCHF) is a severe tick-borne disease well recognized through Europe and Asia where diagnostic tests and medical surveillance are available. However, it is largely neglected in Africa, especially in the tropical rainforest of Central Africa where only sporadic human cases have been reported and date back to more than 30 years. We describe here an isolated human case that occurred in the Democratic Republic of the Congo in 2008 and performed phylogenetic analysis to investigate whether it resulted from a regional re-emergence or from the introduction of a novel virus in the area. Methods and Findings: Near complete segment S and partial segment M sequences were characterized. Bayesian phylogenetic analysis and datation were performed to investigate the relationship between this new strain and viral strains from Africa, Europe and Asia. The new strain is phylogenetically close to the previously described regional genotype (II) that appears to be specific to Central Africa.
    [Show full text]
  • REPORT of the SCIENTIFIC TASK FORCE on PREVENTING PANDEMICS Dr
    AUGUST 2021 REPORT OF THE SCIENTIFIC TASK FORCE ON PREVENTING PANDEMICS Dr. Yewande Alimi, Dr. Aaron Bernstein, Dr. Jonathan Epstein, Dr. Marcos Espinal, Dr. Manish Kakkar, Dr. Deborah Kochevar, Dr. Guilherme Werneck Report of the Scientific Task Force on Preventing Pandemics Convened by the Harvard Global Health Institute and the Center for Climate, Health, and the Global Environment at Harvard T.H. Chan School of Public Health Task Force Members Dr. Yewande Alimi, Antimicrobial resistance (AMR) and One Health Program Coordinator at Africa Centres for Disease Control and Prevention, Africa Union Dr. Aaron Bernstein, Task Force Chair; Interim Director, Center for Climate, Health, and the Global Environment, Harvard T.H. Chan School of Public Health; Faculty Lead, Climate Change and Health Initiative, Harvard Global Health Institute; Pediatrician, Boston Children’s Hospital Dr. Jonathan Epstein, Vice President for Science and Outreach, EcoHealth Alliance Dr. Marcos Espinal, Director of Communicable Diseases and Environmental Determinants of Health, Pan American Health Organization Dr. Manish Kakkar, Senior Public Health Specialist, New Delhi, India Dr. Deborah Kochevar, Professor, Comparative Pathobiology and Dean Emerita Cummings School of Veterinary Medicine; Senior Fellow, The Fletcher School at Tufts University Dr. Guilherme Werneck, Professor of Epidemiology at the State University of Rio de Janeiro The task force members who contributed to this report have done so as individuals and not as representatives of their organizations.
    [Show full text]
  • African Origin of the Malaria Parasite Plasmodium Vivax
    ARTICLE Received 11 Sep 2013 | Accepted 29 Jan 2014 | Published 21 Feb 2014 DOI: 10.1038/ncomms4346 African origin of the malaria parasite Plasmodium vivax Weimin Liu1, Yingying Li1, Katharina S. Shaw2,GeraldH.Learn1, Lindsey J. Plenderleith3,JordanA.Malenke1, Sesh A. Sundararaman1,4,MiguelA.Ramirez1,PatriciaA.Crystal1,AndrewG.Smith1, Frederic Bibollet-Ruche1, Ahidjo Ayouba5, Sabrina Locatelli5, Amandine Esteban5, Fatima Mouacha5, Emilande Guichet5, Christelle Butel5, Steve Ahuka-Mundeke5,6, Bila-Isia Inogwabini7,Jean-BoscoN.Ndjango8, Sheri Speede9, Crickette M. Sanz10,11, David B. Morgan11,12, Mary K. Gonder13, Philip J. Kranzusch14,PeterD.Walsh15,AlexanderV.Georgiev16,w, Martin N. Muller17,AlexK.Piel15,18,FionaA.Stewart15, Michael L. Wilson19, Anne E. Pusey20,LiwangCui21, Zenglei Wang21, Anna Fa¨rnert22, Colin J. Sutherland23, Debbie Nolder23, John A. Hart24, Terese B. Hart24, Paco Bertolani25, Amethyst Gillis26, Matthew LeBreton26, Babila Tafon27,JohnKiyang28, Cyrille F. Djoko26, Bradley S. Schneider26,NathanD.Wolfe26, Eitel Mpoudi-Ngole29, Eric Delaporte5,RichardCarter30,31,RichardL. Culleton32,GeorgeM.Shaw1,4,JulianC.Rayner33, Martine Peeters5,BeatriceH.Hahn1,4 &PaulM.Sharp3,31 Plasmodium vivax is the leading cause of human malaria in Asia and Latin America but is absent from most of central Africa due to the near fixation of a mutation that inhibits the expression of its receptor, the Duffy antigen, on human erythrocytes. The emergence of this protective allele is not understood because P. vivax is believed to have originated in Asia. Here we show, using a non- invasive approach, that wild chimpanzees and gorillas throughout central Africa are endemically infected with parasites that are closely related to human P. vivax. Sequence analyses reveal that ape parasites lack host specificity and are much more diverse than human parasites, which form a monophyletic lineage within the ape parasite radiation.
    [Show full text]